Year To Quarter End Consolidated Statement Of Comprehensive Income

JCR Pharmaceuticals Co.,Ltd. - Filing #7251173

Concept 2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
Year to quarter end consolidated statement of comprehensive income
Statement of comprehensive income
Profit (loss)
-4,695,000,000 JPY
-4,746,000,000 JPY
-4,746,000,000 JPY
-4,746,000,000 JPY
-4,746,000,000 JPY
6,364,000,000 JPY
5,536,000,000 JPY
6,364,000,000 JPY
6,364,000,000 JPY
6,364,000,000 JPY
Other comprehensive income
Valuation difference on available-for-sale securities
195,000,000 JPY
185,000,000 JPY
Deferred gains or losses on hedges
3,000,000 JPY
0 JPY
Foreign currency translation adjustment
130,000,000 JPY
166,000,000 JPY
Remeasurements of defined benefit plans, net of tax
-78,000,000 JPY
153,000,000 JPY
Share of other comprehensive income of entities accounted for using equity method
401,000,000 JPY
434,000,000 JPY
Other comprehensive income
652,000,000 JPY
939,000,000 JPY
Comprehensive income
-4,043,000,000 JPY
6,475,000,000 JPY
Comprehensive income attributable to
Comprehensive income attributable to owners of parent
-4,139,000,000 JPY
6,430,000,000 JPY
Comprehensive income attributable to non-controlling interests
96,000,000 JPY
44,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.